*FDA approved in 1985, the first GnRHa for the treatment of advanced prostate cancer patients.1
Lucas, age 64
Semi-retired financial analyst, passionate cook,
husband and father
Not an actual patient.
LUPRON DEPOT, an androgen deprivation therapy (ADT), has been a pioneer in the treatment of advanced prostate cancer.1
A Wealth of Experience
Our commitment to your patients will be as strong tomorrow as it is today.
#1 Prescribed
America’s most-prescribed
GnRHa2†
35+ Years
The most clinical experience of
any GnRHa on the market1‡
Millions of injections
administered3§
A Number of Firsts
From day 1, LUPRON DEPOT has been committed to the treatment of advanced prostate cancer.
1985
LUPRON DEPOT became the first approved GnRHa for the palliative treatment of advanced prostate cancer1
1989
First and only GnRHa prefilled dual-chamber syringe. No external mixing required. Flexible dosing options4-11
2007
Launched LuproLink Inventory Management System
2016
Dosage and administration section of the label updated to include continued treatment in patients who develop metastatic CRPC4,11
2019
Dosage and administration section of the label updated to include continued treatment in patients who develop nonmetastatic or metastatic CRPC4,11
2022
LUPRON DEPOT is indicated for treatment of advanced prostate cancer4
CRPC=castration-resistant prostate cancer.
Coverage
We are committed to making LUPRON DEPOT accessible for patients.
>99%
of lives
LUPRON DEPOT is covered for >99% of lives with national commercial insurance, Medicaid, and Medicare Part B combined12*†
~100%
covered
LUPRON DEPOT is covered for ~100% of Medicare Part B lives12*†
Overview of Medicare Part B and D
Medicare
Part B
Part B is a medical benefit that covers services such as in-office administration for medications like LUPRON DEPOT
Part B may offer lower out-of-pocket costs for patients compared with Part D or commercial insurance pharmacy benefits
Medicare
Part D
Part D is a prescription drug benefit that covers medications dispensed through a pharmacy
Part D may have higher out-of-pocket costs than Part B
Source: Managed Markets Insight and Technology, LLC, a trademark of MMIT, as of November 2024. This analysis reflects medical insurance coverage only. |
| * | For those national commercial, Medicaid, and Medicare plans that report coverage data; excludes plans and payors with unknown coverage. |
| † | Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies. |
"...decades of experience in using LUPRON DEPOT in my practice continues to reinforce my confidence in prescribing it as my first choice for patients with advanced prostate cancer."